Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

INCY Relative to the S&P 500

INCY Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Incyte Corp. (NASD:INCY) seasonal charts above shows that a Buy Date of October 27 and a Sell Date of January 15 has resulted in a geometric average return of 11.71% above the benchmark rate of the S&P 500 Total Return Index over the past 20 years. This seasonal timeframe has shown positive results compared to the benchmark in 14 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 20 years by an average of 6.69% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Incyte focuses on the discovery and development of small-molecule drugs. The firm’s lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte’s other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm’s first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte’s pipeline includes a broad array of oncology and dermatology programs.

To download INCY seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: INCY